J Headache Pain (2005) 6:143–148 DOI 10.1007/s10194-005-0169-y ORIGINAL Zulfi Engindeniz Intramuscular tramadol vs. diclofenac sodium Celaleddin Demircan Necdet Karli for the treatment of acute migraine attacks Erol Armagan in emergency department: a prospective, Mehtap Bulut Tayfun Aydin randomised, double-blind study Mehmet Zarifoglu Received: 6 February 2005 Abstract The aim of this prospec- injection in future visits. Any Accepted in revised form: 15 April 2005 tive, randomised, double-blind study adverse events, whether related to Published online: 13 May 2005 was to evaluate the efficacy of intra- the drug or not, were also recorded. muscular (IM) tramadol 100 mg in Patients were followed up by tele- emergency department treatment of phone 48 h later to check for any acute migraine attack and to com- headache recurrence. Two-hour pain pare it with that of IM diclofenac response rate, which was the prima- sodium 75 mg. Forty patients who ry endpoint, was 80% for both tra- were admitted to our emergency madol and diclofenac groups. There department with acute migraine were no statistically significant dif- attack according to the International ferences among groups in terms of Z. Engindeniz (౧) • E. Armagan • M. Bulut Headache Society criteria were 48-h pain response, rescue treat- T. Aydin Department of Emergency Medicine, included in the study. Patients were ment, associated symptoms’ Uludag University Medical Faculty, randomised to receive either tra- response, headache recurrence and Acil Tip ABD Gorukle, madol 100 mg (n=20) or diclofenac adverse event rates. Fifteen (75%) Bursa 16059, Turkey sodium 75 mg (n=20) intramuscular- patients in the tramadol group and e-mail:
[email protected] ly.